keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/29327220/patient-perceptions-and-preferences-for-a-mealtime-insulin-delivery-patch
#1
Mark Peyrot, Darlene Dreon, Vivien Zraick, Brett Cross, Meng H Tan
INTRODUCTION: A basal-bolus insulin regimen is needed to achieve glycated hemoglobin A1c (HbA1c) below 7.0% in people with type 1 (T1D) or type 2 (T2D) diabetes who have significant loss of beta-cell function. Nonadherence to therapy is common and negatively affects the ability to reach treatment goals. We examined patient assessment of a new, wearable mealtime insulin-delivery system (patch) relative to their current mealtime insulin-delivery system (syringe, pen, or pump). The patch is designed to deliver only boluses of fast-acting insulin (no basal insulin), mechanically controlled by the patient...
January 11, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29320718/adiposity-and-family-history-of-type-2-diabetes-in-an-admixed-population-of-adolescents-associations-with-insulin-sensitivity-beta-cell-function-and-hepatic-insulin-extraction-in-brams-study
#2
Daniella F Camilo, Ana Carolina J Vasques, Keila Hayashi, Andrea Tura, Cleliani de Cassia da Silva, Mariana P Zambon, Maria Ângela R de G Monteiro Antônio, Bruno Geloneze
AIMS: Insulin resistance and beta-cell dysfunction manifest differently across racial/ethnic groups, and there is a lack of knowledge regarding the pathophysiology of type 2 diabetes mellitus (T2DM) for ethnically admixed adolescents. This study aimed to investigate the influence of adiposity and family history (FH) of T2DM on aspects of insulin sensitivity, beta-cell function, and hepatic insulin extraction in Brazilian adolescents. METHODS: A total of 82 normoglycemic adolescents were assessed...
January 7, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29318537/glucose-control-and-weight-change-associated-with-treatment-with-exenatide-compared-with-basal-insulin-a%C3%A2-retrospective-study
#3
Christopher Ll Morgan, Qing Qiao, Susan Grandy, Kristina Johnsson, Sara Jenkins-Jones, Sarah Holden, Craig J Currie
INTRODUCTION: The aim of the study was to compare glycemic and weight change outcomes for type 2 diabetes patients treated with either exenatide once-weekly (EQW) or exenatide twice-daily (EBID) with those patients treated with basal insulin (BI). METHODS: Retrospective data (2010-2014) were extracted from the Clinical Practice Research Datalink, a UK primary care database. Patients previously naïve to injectable therapy initiating EQW, EBID, or BI were extracted and matched by propensity score within two analyses (EQW vs BI and EBID vs BI)...
January 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29316236/long-term-safety-and-efficacy-of-tofogliflozin-add-on-to-insulin-in-patients-with-type-2-diabetes-results-from-a-52-week-multicenter-randomized-double-blind-open-label-extension-phase-4-study-in-japan-j-step-ins
#4
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
AIMS: To evaluate the long-term safety and efficacy of tofogliflozin as an add-on treatment to insulin over 52 weeks. MATERIALS AND METHODS: This 52-week, multicenter, Phase 4 study consisted of a 16-week, randomized, double-blind, placebo-controlled phase and a 36-week open label extension phase (NCT02201004). Japanese patients with type 2 diabetes mellitus aged 20-75 years with suboptimal glycemic control (7.5%-10.5%) on insulin monotherapy (basal-bolus, bolus, premix [low and high], and basal) or on combination therapy of basal insulin and dipeptidyl peptidase-4 inhibitor were eligible for participation...
January 5, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29316176/effect-of-prandial-treatment-timing-adjustment-based-on-continuous-glucose-monitoring-in-patients-with-type-2-diabetes-uncontrolled-on-once-daily-basal-insulin-a-randomized-phase-iv-study
#5
Jacob Ilany, Hamad Bhandari, Dan Nabriski, Yoel Toledano, Noa Konvalina, Ohad Cohen
OBJECTIVE: To evaluate the glycemic control achieved by prandial once daily insulin glulisine injection timing adjustment based on continuous glucose monitoring sensor in comparison to once daily insulin glulisine injection before breakfast in type 2 diabetes patients uncontrolled on once daily basal insulin glargine. RESEARCH DESIGN AND METHODS: This was a 24-week open-label, randomized-controlled, multicenter trial. At the end of 8 weeks of basal insulin optimization period, patients with HbA1c ≥ 7...
January 8, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29316141/the-association-of-hypoglycaemia-severity-and-clinical-patient-reported-and-economic-outcomes-in-us-patients-with-type-2-diabetes-using-basal-insulin
#6
Luigi F Meneghini, Lulu Lee, Shaloo Gupta, Ron Preblick
AIMS: To evaluate the clinical and patient-reported outcomes and healthcare utilization and costs associated with patient-reported hypoglycaemia in US adults with type 2 diabetes (T2D) treated with basal insulin. MATERIALS AND METHODS: This was an observational, cross-sectional, survey-based study of adults with T2D on basal insulin ± oral antidiabetes drugs (OADs) or rapid-acting/premix insulin who had in the past ever experienced hypoglycaemia, using US data from the National Health and Wellness Survey...
January 5, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29314667/clinical-characteristics-of-type-2-diabetes-patients-with-discordance-between-hba1c-and-fasting-plasma-glucose-in-the-real-world-an-analysis-of-the-orbit-study
#7
Hua Shu, Juming Lu, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Fang Zhao, Linong Ji
BACKGROUND: We aimed to determine the clinical characteristics of type 2 diabetes patients on basal insulin therapy with inadequate glucose control due to discordance between glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in the real world. METHODS: This was a retrospective analysis of data from the ORBIT study in China. Clinical characteristics of patients with discordance between HbA1c and FPG at baseline and at the end of 6 months of follow-up were analyzed using multinomial logistic regression in 4 study groups devided by HbA1c and FPG...
January 3, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29313285/treatment-dosing-patterns-and-clinical-outcomes-for-patients-with-type-2-diabetes-starting-or-switching-to-treatment-with-insulin-glargine-300-units-per-milliliter-in-a-real-world-setting-a-retrospective-observational-study
#8
Shaloo Gupta, Hongwei Wang, Neil Skolnik, Liyue Tong, Ryan M Liebert, Lulu K Lee, Peter Stella, Anna Cali, Ronald Preblick
INTRODUCTION: Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter (Gla-300) have not been studied in real-world clinical practice. This study evaluated differences in dosing and clinical outcomes before and after Gla-300 treatment initiation in patients with type 2 diabetes starting or switching to treatment with Gla-300 to assess whether the benefits observed in clinical trials translate into real-world settings...
January 8, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29300101/quality-of-life-and-treatment-satisfaction-in-actual-clinical-practice-of-patients-with-type-1-diabetes-mellitus-t1dm-and-hypoglycemia-treated-with-insulin-degludec
#9
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez, Domingo Orozco
OBJECTIVE: The frequency of hypoglycemia in patients with T1DM is high and results in a poorer quality of life and low treatment satisfaction. The aim of our study is to demonstrate the effect of changing the basal insulin (glargine or detemir) to insulin degludec. METHODS: We conducted an observational analytical study on a cohort of 110 patients with T1DM. The patients were administered 3 questionnaires to assess treatment satisfaction (DTSQ-s), fear of hypoglycemia (HFS-II) and quality of life (EQ-5D), before the change and at 6 months...
January 4, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29289540/a-randomized-controlled-study-comparing-a-dpp4-inhibitor-linagliptin-and-basal-insulin-glargine-in-patients-with-type-2-diabetes-in-long-term-care-and-skilled-nursing-facilities-linagliptin-ltc-trial
#10
Guillermo E Umpierrez, Saumeth Cardona, David Chachkhiani, Maya Fayfman, Sahebi Saiyed, Heqiong Wang, Priyathama Vellanki, J Sonya Haw, Darin E Olson, Francisco J Pasquel, Theodore M Johnson
OBJECTIVES: Safe and easily implemented treatment regimens are needed for the management of patients with type 2 diabetes mellitus (T2DM) in long-term care (LTC) and skilled nursing facilities. DESIGN: This 6-month open-label randomized controlled trial compared the efficacy and safety of a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in LTC residents with T2DM. SETTINGS: Three LTC institutions affiliated with a community safety-net hospital, US Department of Veterans Affairs and Emory Healthcare System in Atlanta, Georgia...
December 27, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/29278460/relationship-between-treatment-persistence-and-a1c-trends-among-patients-with-type-2-diabetes-newly-initiated-on-basal-insulin
#11
Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick, Luigi Meneghini
This study examines the relationship between glycated hemoglobin (A1C) levels and treatment persistence with, or time to discontinuation of, basal insulin in patients with type 2 diabetes (T2D) newly initiating insulin. Claims data were extracted from the Optum™ Clinformatics database from January 2010 to June 2015. Adult patients with T2D initiating insulin glargine 100 U/mL (Gla-100) or insulin detemir (DET) with ≥1 A1C measurement during 12-month baseline and 18-month follow-up periods were included...
December 26, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29277968/efficacy-and-safety-of-adding-liraglutide-to-existing-insulin-regimens-in-japanese-subjects-with-type-2-diabetes-mellitus-a-post-hoc-analysis-of-a-phase-3-randomized-clinical-trial
#12
Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch-Traberg, Kohei Kaku, Yutaka Seino
AIMS: To determine the efficacy and safety of adding liraglutide to three different insulin regimens in Japanese subjects with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: In this post hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported. Subjects with T2DM were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix). The primary objective was to determine whether adding liraglutide (0...
December 26, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29277378/assessment-of-hypoglycaemia-during-basal-insulin-therapy-temporal-distribution-and-risk-of-events-using-a-predefined-or-an-expanded-definition-of-nocturnal-events
#13
M C Riddle, G B Bolli, A Avogaro, M G Álvarez, A Merino-Trigo, E Boëlle-Le Corfec, P D Home
AIM: To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the frequency of nocturnal events based on a predefined nocturnal window or an expanded interval, using illustrative data for two insulin glargine formulations. METHODS: Temporal distribution of hypoglycaemic events was assessed descriptively and by profile using participant-level data from three randomized trials comparing insulin glargine 300 U/mL (Gla-300) and 100 U/mL (Gla-100)...
December 11, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29276400/challenges-and-unmet-needs-in-basal-insulin-therapy-lessons-from-the-asian-experience
#14
REVIEW
Wing Bun Chan, Jung Fu Chen, Su-Yen Goh, Thi Thanh Huyen Vu, Iris Thiele Isip-Tan, Sony Wibisono Mudjanarko, Shailendra Bajpai, Maria Aileen Mabunay, Pongamorn Bunnag
Basal insulin therapy can improve glycemic control in people with type 2 diabetes. However, timely initiation, optimal titration, and proper adherence to prescribed basal insulin regimens are necessary to achieve optimal glycemic control. Even so, glycemic control may remain suboptimal in a significant proportion of patients. Unique circumstances in Asia (eg, limited resources, management of diabetes primarily in nonspecialist settings, and patient populations that are predominantly less educated) coupled with the limitations of current basal insulin options (eg, risk of hypoglycemia and dosing time inflexibility) amplify the challenge of optimal basal insulin therapy in Asia...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29276398/cost-effectiveness-analysis-of-ideglira-versus-basal-bolus-insulin-for-patients-with-type-2-diabetes-in-the-slovak-health-system
#15
Marek Psota, Maria Bucek Psenkova, Natalia Racekova, Antonio Ramirez de Arellano, Tom Vandebrouck, Barnaby Hunt
Aims: To investigate the cost-effectiveness of once-daily insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in patients with type 2 diabetes not meeting glycemic targets on basal insulin from a healthcare payer perspective in Slovakia. Methods: Long-term clinical and economic outcomes for patients receiving IDegLira and basal-bolus therapy were estimated using the IMS CORE Diabetes Model based on a published pooled analysis of patient-level data...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29273469/circulating-triacylglycerols-but-not-pancreatic-fat-associate-with-insulin-secretion-in-healthy-humans
#16
Bettina Nowotny, Sabine Kahl, Birgit Klüppelholz, Barbara Hoffmann, Guido Giani, Roshan Livingstone, Peter J Nowotny, Valerie Stamm, Christian Herder, Andrea Tura, Giovanni Pacini, Jong-Hee Hwang, Michael Roden
BACKGROUND: Loss of adequate insulin secretion for the prevailing insulin resistance is critical for the development of type 2 diabetes and has been suggested to result from circulating lipids (triacylglycerols [TG] or free fatty acids) and/or adipocytokines or from ectopic lipid storage in the pancreas. This study aimed to address whether circulating lipids, adipocytokines or pancreatic fat primarily associate with lower insulin secretion. SUBJECTS/METHODS: Nondiabetic persons (n=73), recruited from the general population, underwent clinical examinations, fasting blood drawing to measure TG and adipocytokines and oral glucose tolerance testing (OGTT) to assess basal and dynamic insulin secretion and sensitivity indices...
December 19, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29260929/switching-basal-insulins-in-type-2-diabetes-practical-recommendations-for-health-care-providers
#17
Sarah L Anderson, Jennifer M Trujillo, John E Anderson, Robert J Tanenberg
Basal insulin remains the mainstay of treatment of type 2 diabetes when diet changes and exercise in combination with oral drugs and other injectable agents are not sufficient to control hyperglycemia. Insulin therapy should be individualized, and several factors influence the choice of basal insulin; these include pharmacological properties, patient preferences, and lifestyle, as well as health insurance plan formularies. The recent availability of basal insulin formulations with longer durations of action has provided further dosing flexibility; however, patients may need to switch agents throughout therapy for a variety of personal, clinical, or economic reasons...
December 20, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/29232162/efficacy-and-safety-of-biosimilar-sar342434-insulin-lispro-in-adults-with-type-2-diabetes-also-using-insulin-glargine-sorella-2-study
#18
Karl-Michael Derwahl, Timothy S Bailey, Karin Wernicke-Panten, Lin Ping, Suzanne Pierre
BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog®; Ly-Lis). This study aimed to show similar efficacy, safety, and immunogenicity of SAR-Lis versus Ly-Lis in adult patients with type 2 diabetes mellitus (T2DM) treated with multiple daily injections, while using insulin glargine (GLA-100; Lantus®) as basal insulin. METHODS: SORELLA 2 was a 6-month, randomized, open-label, Phase 3 study (NCT02294474). Insulin doses were adjusted to achieve fasting and 2-h postprandial glucose targets according to American Diabetes Association guidelines...
December 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29229615/defective-amplifying-pathway-of-%C3%AE-cell-secretory-response-to-glucose-in-type-2-diabetes-integrated-modeling-of-in-vitro-and-in-vivo-evidence
#19
Eleonora Grespan, Toni Giorgino, Silva Arslanian, Andrea Natali, Ele Ferrannini, Andrea Mari
In vivo studies have investigated the role of β-cell dysfunction in type 2 diabetes (T2D), while in vitro research on islets has elucidated key mechanisms controlling insulin secretion rate (ISR). However, the relevance of the cellular mechanisms identified in vitro, i.e., the triggering and amplifying pathways, has not been established in vivo Furthermore, the mechanisms underpinning β-cell dysfunction in T2D remain undetermined. We propose a unifying explanation of several characteristic features of insulin secretion, both in vitro and in vivo, using a mathematical model...
December 11, 2017: Diabetes
https://www.readbyqxmd.com/read/29225892/correlates-of-second-line-type-2-diabetes-medication-selection-in-the-usa
#20
Ronald T Ackermann, Amisha Wallia, Matthew J O'Brien, Raymond Kang, Andrew Cooper, Margaret R Moran, David T Liss
Objective: Past research provides insufficient evidence to inform second-line diabetes medication prescribing when metformin is no longer sufficient. We evaluated patient, prescriber, and health plan characteristics associated with selection of second-line diabetes medications in the USA. Research design and methods: We used a multiple case-comparison study design to identify characteristics associated with the probability of starting each of six second-line diabetes medication alternatives within 77 744 adults enrolled in commercial or Medicare Advantage health plans from 2011 to 2015...
2017: BMJ Open Diabetes Research & Care
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"